Cargando…
Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers
BACKGROUND: Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the v...
Autores principales: | Atallah, Bassam, El Nekidy, Wasim, Mallah, Saad I., Cherfan, Antoine, AbdelWareth, Laila, Mallat, Jihad, Hamed, Fadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479301/ https://www.ncbi.nlm.nih.gov/pubmed/32922212 http://dx.doi.org/10.1186/s12959-020-00236-9 |
Ejemplares similares
-
Thromboelastography findings in critically ill COVID-19 patients
por: Salem, Nouran, et al.
Publicado: (2020) -
Tocilizumab and COVID-19: Timing of Administration and Efficacy
por: Abidi, Emna, et al.
Publicado: (2022) -
Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs
por: Abidi, Emna, et al.
Publicado: (2023) -
Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome
por: Gupta, Sudeendra, et al.
Publicado: (2020) -
Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy
por: Attallah, Nizar, et al.
Publicado: (2021)